Functional imaging for prostate cancer: Therapeutic implications

Seminars in Nuclear Medicine

Volumn 42, Issue 5, 2012, Pages 328-342

  Mari Aparici, Carina ^a,b   Seo, Youngho ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; ALBUMIN TC 99M; ANDROGEN RECEPTOR; ANTIMONY TECHNETIUM SULFIDE TC 99M; CAPROMAB PENDETIDE IN 111; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROTESTOSTERONE F 18; FLUTAMIDE; MEDRONATE TECHNETIUM TC 99M; METHIONINE C 11; MIP 1072 I 123; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; SODIUM FLUORIDE F 18; TECHNETIUM SULFUR COLLOID TC 99M; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BONE METASTASIS; BONE TURNOVER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; HUMAN; LYMPH NODE IRRADIATION; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SATISFACTION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN SYNTHESIS; RADIOIMMUNOTHERAPY; REVIEW; SENTINEL LYMPH NODE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIONUCLIDE IMAGING;

EID: 84864413089     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2012.04.004     Document Type: Review

References (204)

1. R. Siegel, D. Naishadham, A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. D. Cho, C.J. Di Blasio, A.C. Rhee Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT) Urol Oncol 21 2003 282 291
3. M. Han, A.W. Partin, S. Piantadosi Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer J Urol 166 2001 416 419
4. T.A. Stamey, M. Caldwell, J.E. McNeal The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 172 2004 1297 1301
5. P. Hammerer, H. Huland, A. Sparenberg Digital rectal examination, imaging, and systematic-sextant biopsy in identifying operable lymph node-negative prostatic carcinoma Eur Urol 22 1992 281 287
6. D.F. Gleason Histologic grading of prostate cancer: A perspective Hum Pathol 23 1992 273 279
7. A. Briganti, P.I. Karakiewicz, F.K. Chun Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection Eur Urol 51 2007 1573 1581
8. K. Touijer, F. Rabbani, J.R. Otero Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1% J Urol 178 2007 120 124
9. M.E. Allaf, G.S. Palapattu, B.J. Trock Anatomical extent of lymph node dissection: Impact on men with clinically localized prostate cancer J Urol 172 2004 1840 1844
10. A. Briganti, N. Suardi, P. Capogrosso Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum Prostate 72 2012 186 192
11. A. Briganti, F.K. Chun, A. Salonia Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy Urology 69 2007 147 151
12. F.C. Burkhard, U.E. Studer The role of lymphadenectomy in high risk prostate cancer World J Urol 26 2008 231 236
13. S.A. Seaward, V. Weinberg, P. Lewis Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation Cancer J Sci Am 4 1998 370 377
14. S.A. Seaward, V. Weinberg, P. Lewis Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer Int J Radiat Oncol Biol Phys 42 1998 1055 1062
15. S.O. Asbell, J.M. Krall, M.V. Pilepich Elective pelvic irradiation in stage A2, B carcinoma of the prostate: Analysis of RTOG 77-06 Int J Radiat Oncol Biol Phys 15 1988 1307 1316
16. H.A. Shih, M. Harisinghani, A.L. Zietman Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy Int J Radiat Oncol Biol Phys 63 2005 1262 1269
17. M. Roach 3rd, M. DeSilvio, R. Valicenti Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial Int J Radiat Oncol Biol Phys 66 2006 647 653
18. A. Wang-Chesebro, P. Xia, J. Coleman Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer Int J Radiat Oncol Biol Phys 66 2006 654 662
19. I. Deutsch, M.J. Zelefsky, Z. Zhang Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT Brachytherapy 9 2011 313 318
20. R.J. Ellis, H. Zhou, D.A. Kaminsky Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion Brachytherapy 6 2007 149 156
21. R.J. Ellis, H. Zhou, E.Y. Kim Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide Brachytherapy 6 2007 16 25
22. P. Ghadjar, C.A. Rentsch, B. Isaak Urethral toxicity vs. cancer control - Lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer Brachytherapy 10 2011 286 294
23. I.C. Hsu, A.R. Cabrera, V. Weinberg Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer Brachytherapy 4 2005 202 206
24. C.R. King LDR vs HDR brachytherapy for localized prostate cancer: The view from radiobiological models Brachytherapy 1 2002 219 226
25. I.C. Hsu, B. Pickett, K. Shinohara Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: Potential for dose escalation Int J Radiat Oncol Biol Phys 46 2000 851 858
26. J. Pouliot, Y. Kim, E. Lessard Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging Int J Radiat Oncol Biol Phys 59 2004 1196 1207
27. P. Ghadjar, O. Matzinger, B. Isaak Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer Radiother Oncol 91 2009 237 242
28. T.Y. Eng, C.R. Thomas, T.S. Herman Primary radiation therapy for localized prostate cancer Urol Oncol 7 2002 239 257
29. H. Hricak, P.L. Choyke, S.C. Eberhardt Imaging prostate cancer: A multidisciplinary perspective Radiology 243 2007 28 53
30. E.N. van Lin, J.J. Fütterer, S.W. Heijmink IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI Int J Radiat Oncol Biol Phys 65 2006 291 303
31. S.M. Noworolski, R.G. Henry, D.B. Vigneron Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI Magn Reson Med 53 2005 249 255
32. J.O. Barentsz, J.J. Fütterer, S. Takahashi Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients Eur J Radiol 63 2007 369 372
33. M.G. Harisinghani, M.A. Saksena, P.F. Hahn Ferumoxtran-10-enhanced MR lymphangiography: Does contrast-enhanced imaging alone suffice for accurate lymph node characterization? Am J Roentgenol 186 2006 144 148
34. J. Lian, S. Hunjan, C. Dumoulin Integrating deformable MRI/MRSI and CT image registration into the prostate IMRT treatment planning Int J Radiat Oncol Biol Phys 57 2003 S207
35. J. Kurhanewicz, M.G. Swanson, S.J. Nelson Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer J Magn Reson Imaging 16 2002 451 463
36. U.G. Mueller-Lisse, M.G. Swanson, D.B. Vigneron Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging Magn Reson Med 46 2001 49 57
37. M.G. Swanson, D.B. Vigneron, T.K. Tran Magnetic resonance imaging and spectroscopic imaging of prostate cancer Cancer Invest 19 2001 510 523
38. K.M. Brindle, S.E. Bohndiek, F.A. Gallagher Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopy Magn Reson Med 66 2011 505 519
39. J. Kurhanewicz, D.B. Vigneron, K. Brindle Analysis of cancer metabolism by imaging hyperpolarized nuclei: Prospects for translation to clinical research Neoplasia 13 2011 81 97
40. Y. Seo, C. Mari, B.H. Hasegawa Technological development and advances in single-photon emission computed tomography/computed tomography Semin Nucl Med 38 2008 177 198
41. S.R. Cherry Multimodality imaging: Beyond PET/CT and SPECT/CT Semin Nucl Med 39 2009 348 353
42. A. Bockisch, L.S. Freudenberg, D. Schmidt Hybrid imaging by SPECT/CT and PET/CT: Proven outcomes in cancer imaging Semin Nucl Med 39 2009 276 289
43. F.V. Coakley, A. Qayyum, J. Kurhanewicz Magnetic resonance imaging and spectroscopic imaging of prostate cancer J Urol 170 2003 S69 S75 discussion S75-S76
44. J. Kurhanewicz, M.G. Swanson, P.J. Wood Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials Urology 57 2001 124 128
45. G. Mariani, L. Bruselli, T. Kuwert A review on the clinical uses of SPECT/CT Eur J Nucl Med Mol Imaging 37 2010 1959 1985
46. B.H. Hasegawa, K.H. Wong, K. Iwata Dual-modality imaging of cancer with SPECT/CT Technol Cancer Res Treat 1 2002 449 458
47. Y. Seo, K.H. Wong, M. Sun Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system J Nucl Med 46 2005 868 877
48. C.M. Aparici, D. Carlson, N. Nguyen Combined SPECT and multidetector CT for prostate cancer evaluations Am J Nucl Med Mol Imaging 2 2012 48 54
49. Y. Seo, C.M. Aparici, C.P. Chen Mapping of lymphatic drainage from the prostate using filtered 99mTc-sulfur nanocolloid and SPECT/CT J Nucl Med 52 2011 1068 1072
50. S.H. Warncke, A. Mattei, F.G. Fuechsel Detection rate and operating time required for gamma probe-guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging Eur Urol 52 2007 126 132
51. M.W. Saif, I. Tzannou, N. Makrilia Role and cost effectiveness of PET/CT in management of patients with cancer Yale J Biol Med 83 2010 53 65
52. H. Otsuka, N. Morita, K. Yamashita FDG-PET/CT for cancer management J Med Invest 54 2007 195 199
53. J. Czernin, H.R. Schelbert PET/CT in cancer patient management Introduction J Nucl Med 48 suppl 1 2007 2S 3S
54. K. Endo, N. Oriuchi, T. Higuchi PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients Int J Clin Oncol 11 2006 286 296
55. R. Bar-Shalom, N. Yefremov, L. Guralnik Clinical performance of PET/CT in evaluation of cancer: Additional value for diagnostic imaging and patient management J Nucl Med 44 2003 1200 1209
56. A.K. Buck, K. Herrmann, C. Shen Molecular imaging of proliferation in vivo: Positron emission tomography with [18F]fluorothymidine Methods 48 2009 205 215
57. K. Ott, K. Herrmann, T. Schuster Molecular imaging of proliferation and glucose utilization: Utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer Ann Surg Oncol 18 2011 3316 3323
58. H. Schöder, S.M. Larson Positron emission tomography for prostate, bladder, and renal cancer Semin Nucl Med 34 2004 274 292
59. E. Fricke, S. Machtens, M. Hofmann Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients Eur J Nucl Med Mol Imaging 30 2003 607 611
60. G.J. Cook, C. Parker, S. Chua 18F-fluoride PET: Changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin) EJNMMI Res 1 2011 4
61. W. Langsteger, S. Balogova, V. Huchet Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: Prospective comparison of diagnostic performance determined by masked reading Q J Nucl Med Mol Imaging 55 2011 448 457
62. M. Beheshti, W. Langsteger, I. Fogelman Prostate cancer: Role of SPECT and PET in imaging bone metastases Semin Nucl Med 39 2009 396 407
63. M. Beheshti, R. Vali, P. Waldenberger Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: A comparative study Eur J Nucl Med Mol Imaging 35 2008 1766 1774
64. W.K. Hsu, M.S. Virk, B.T. Feeley Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT J Nucl Med 49 2008 414 421
65. E. Even-Sapir, U. Metser, E. Mishani The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT J Nucl Med 47 2006 287 297
66. M. Picchio, E.G. Spinapolice, F. Fallanca [11C]choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: Comparison with bone scintigraphy Eur J Nucl Med Mol Imaging 39 2012 13 26
67. G. Giovacchini Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline? Eur J Nucl Med Mol Imaging 38 2011 1964 1966
68. C. Fuccio, R. Schiavina, P. Castellucci Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: The preliminary results of a sequential PET/CT study Eur J Nucl Med Mol Imaging 38 2011 1985 1989
69. I. Jambor, R. Borra, J. Kemppainen Functional imaging of localized prostate cancer aggressiveness using 11C-acetate PET/CT and 1H-MR spectroscopy J Nucl Med 51 2010 1676 1683
70. M. Piert, H. Park, A. Khan Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques J Nucl Med 50 2009 1585 1593
71. J.A. Richter, M. Rodríguez, J. Rioja Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment Mol Imaging Biol 12 2010 210 217
72. M. Picchio, C. Crivellaro, G. Giovacchini PET-CT for treatment planning in prostate cancer Q J Nucl Med Mol Imaging 53 2009 245 268
73. B.J. Krause, M. Souvatzoglou, M. Tuncel The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer Eur J Nucl Med Mol Imaging 35 2008 18 23
74. S.N. Reske, N.M. Blumstein, G. Glatting [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy Eur J Nucl Med Mol Imaging 35 2008 9 17
75. C. Nanni, P. Castellucci, M. Farsad 11C/18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended? Eur J Nucl Med Mol Imaging 34 2007 1704 1705
76. B. Scher, M. Seitz, W. Albinger Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer Eur J Nucl Med Mol Imaging 34 2007 45 53
77. G. Martorana, R. Schiavina, B. Corti 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy J Urol 176 2006 954 960 discussion 960
78. S.N. Reske, N.M. Blumstein, B. Neumaier Imaging prostate cancer with 11C-choline PET/CT J Nucl Med 47 2006 1249 1254
79. S. Yoshida, K. Nakagomi, S. Goto 11C-choline positron emission tomography in prostate cancer: Primary staging and recurrent site staging Urol Int 74 2005 214 220
80. I.J. de Jong, J. Pruim, P.H. Elsinga 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer Eur Urol 44 2003 32 38 discussion 38-39
81. M. Picchio, C. Messa, C. Landoni Value of [11C]choline-positron emission tomography for re-staging prostate cancer: A comparison with [18F]fluorodeoxyglucose-positron emission tomography J Urol 169 2003 1337 1340
82. I.J. de Jong, J. Pruim, P.H. Elsinga Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET J Nucl Med 44 2003 331 335
83. M. Picchio, C. Landoni, C. Messa Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer Am J Roentgenol 179 2002 482 484
84. I.J. de Jong, J. Pruim, P.H. Elsinga Visualization of prostate cancer with 11C-choline positron emission tomography Eur Urol 42 2002 18 23
85. T. Hara, N. Kosaka, H. Kishi PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 1998 990 995
86. A. Dimitrakopoulou-Strauss, L.G. Strauss PET imaging of prostate cancer with 11C-acetate J Nucl Med 44 2003 556 558
87. M. Froehner, B. Beuthien-Baumann, M.P. Wirth 11C-acetate positron emission tomography for occult prostate cancer Urol Oncol 24 2006 410 411
88. H. Jadvar Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline J Nucl Med 52 2011 81 89
89. T. Kato, E. Tsukamoto, Y. Kuge Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: Comparison with prostate cancer Eur J Nucl Med Mol Imaging 29 2002 1492 1495
90. J. Kotzerke, B.G. Volkmer, B. Neumaier Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer Eur J Nucl Med Mol Imaging 29 2002 1380 1384
91. E. Mena, B. Turkbey, H. Mani 11C-acetate PET/CT in localized prostate cancer: A study with MRI and histopathologic correlation J Nucl Med 53 2012 538 545
92. N. Oyama, H. Akino, H. Kanamaru 11C-acetate PET imaging of prostate cancer J Nucl Med 43 2002 181 186
93. N. Oyama, T.R. Miller, F. Dehdashti 11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse J Nucl Med 44 2003 549 555
94. C. Schiepers, C.K. Hoh, J. Nuyts 1-11C-acetate kinetics of prostate cancer J Nucl Med 49 2008 206 215
95. D. Soloviev, A. Fini, F. Chierichetti PET imaging with 11C-acetate in prostate cancer: A biochemical, radiochemical and clinical perspective Eur J Nucl Med Mol Imaging 35 2008 942 949
96. A.L. Vāvere, S.J. Kridel, F.B. Wheeler 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer J Nucl Med 49 2008 327 334
97. S. Wachter, S. Tomek, A. Kurtaran 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer J Clin Oncol 24 2006 2513 2519
98. S.L. Rice, C.A. Roney, P. Daumar The next generation of positron emission tomography radiopharmaceuticals in oncology Semin Nucl Med 41 2011 265 282
99. S.M. Larson, M. Morris, I. Gunther Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer J Nucl Med 45 2004 366 373
100. P.B. Zanzonico, R. Finn, K.S. Pentlow PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer J Nucl Med 45 2004 1966 1971
101. H. Zaidi, A. Del Guerra An outlook on future design of hybrid PET/MRI systems Med Phys 38 2011 5667 5689
102. B.J. Pichler, A. Kolb, T. Nägele PET/MRI: Paving the way for the next generation of clinical multimodality imaging applications J Nucl Med 51 2010 333 336
103. A. Fatemi-Ardekani, N. Samavati, J. Tang Advances in multimodality imaging through a hybrid PET/MRI system Crit Rev Biomed Eng 37 2009 495 515
104. G. Delso, S. Ziegler PET/MRI system design Eur J Nucl Med Mol Imaging 36 suppl 1 2009 S86 S92
105. S.R. Banerjee, M. Pullambhatla, Y. Byun 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer J Med Chem 53 2010 5333 5341
106. S.E. Lapi, H. Wahnishe, D. Pham Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer J Nucl Med 50 2009 2042 2048
107. U. Elsässer-Beile, G. Reischl, S. Wiehr PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen J Nucl Med 50 2009 606 611
108. Y. Chen, C.A. Foss, Y. Byun Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer J Med Chem 51 2008 7933 7943
109. E.J. Lepin, J.V. Leyton, Y. Zhou An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors Eur J Nucl Med Mol Imaging 37 2010 1529 1538
110. F. Abdollah, J. Schmitges, M. Sun A population-based assessment of the national comprehensive cancer network practice guideline indications for pelvic lymph node dissection at radical prostatectomy BJU Int 109 2012 1178 1182
111. T.K. Poonacha, R.S. Go Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines J Clin Oncol 29 2011 186 191
112. E.D. Crawford Use of algorithms as determinants for individual patient decision making: National comprehensive cancer network versus artificial neural networks Urology 62 2003 13 19
113. D. Cella, D. Paul, S. Yount What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN) Cancer Invest 21 2003 526 535
114. D. Scherr, P.W. Swindle, P.T. Scardino National Comprehensive Cancer Network guidelines for the management of prostate cancer Urology 61 2003 14 24
115. L.H. Baker, G. Hanks, D. Gershenson NCCN prostate cancer practice guidelines The National Comprehensive Cancer Network Oncology (Williston Park) 10 1996 265 288
116. K. Fizazi, L. Bosserman, G. Gao Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase II trial J Urol 182 2009 509 515 discussion 515-516
117. M.R. Smith Osteoclast targeted therapy for prostate cancer: Bisphosphonates and beyond Urol Oncol 26 2008 420 425
118. T.J. Polascik Bone health in prostate cancer patients receiving androgen-deprivation therapy: The role of bisphosphonates Prostate Cancer Prostatic Dis 11 2008 13 19
119. D. Lüftner, P. Henschke, K. Possinger Clinical value of bisphosphonates in cancer therapy Anticancer Res 27 2007 1759 1768
120. S.M. Gilbert, J.M. McKiernan The role of bisphosphonates in preventing skeletal complications of hormonal therapy Urol Clin North Am 33 2006 191 199 vi
121. M.R. Smith The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy Oncology (Williston Park) 18 5 suppl 3 2004 21 25
122. P.J. Hoskin Bisphosphonates and radiation therapy for palliation of metastatic bone disease Cancer Treat Rev 29 2003 321 327
123. M.R. Smith Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer Drugs Aging 20 2003 175 183
124. A.H. Paterson The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases Cancer 88 2000 3038 3046
125. S. Lutje, O.C. Boerman, C.M. van Rij Prospects in radionuclide imaging of prostate cancer Prostate 2011 Nov 29 [Epub ahead of print]
126. A.J. Beer, M. Eiber, M. Souvatzoglou Radionuclide and hybrid imaging of recurrent prostate cancer Lancet Oncol 12 2011 181 191
127. R.C. Mease Radionuclide based imaging of prostate cancer Curr Top Med Chem 10 2010 1600 1616
128. M.T. Spiotto, S.L. Hancock, C.R. King Radiotherapy after prostatectomy: Improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients Int J Radiat Oncol Biol Phys 69 2007 54 61
129. D. Weckermann, R. Dorn, M. Trefz Sentinel lymph node dissection for prostate cancer: Experience with more than 1,000 patients J Urol 177 2007 916 920
130. W. Meinhardt, H.G. van der Poel, R.A. Valdes Olmos Laparoscopic sentinel lymph node biopsy for prostate cancer: The relevance of locations outside the extended dissection area Prostate Cancer 2012 2012 751753
131. C. Rousseau, T. Rousseau, B. Bridji Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma Eur J Nucl Med Mol Imaging 39 2012 291 299
132. D. Schilling, U. Boekeler, G. Gakis Modified concept for radioisotope-guided sentinel lymph node dissection in prostate cancer World J Urol 28 2010 715 720
133. G. Holl, R. Dorn, H. Wengenmair Validation of sentinel lymph node dissection in prostate cancer: Experience in more than 2,000 patients Eur J Nucl Med Mol Imaging 36 2009 1377 1382
134. C. Bastide, I. Brenot-Rossi, S. Garcia Radioisotope guided sentinel lymph node dissection in patients with localized prostate cancer: Results of the first 100 cases Eur J Surg Oncol 35 2009 751 756
135. W. Meinhardt, R.A. Valdés Olmos, H.G. van der Poel Laparoscopic sentinel node dissection for prostate carcinoma: Technical and anatomical observations BJU Int 102 2008 714 717
136. G. Janetschek Can sentinel pelvic lymph node dissection replace extended pelvic lymph node dissection in patients with prostate cancer? Nat Clin Pract Urol 4 2007 636 637
137. I. Brenot-Rossi, D. Rossi, B. Esterni Radioguided sentinel lymph node dissection in patients with localised prostate carcinoma: Influence of the dose of radiolabelled colloid to avoid failure of the procedure Eur J Nucl Med Mol Imaging 35 2008 32 38
138. S. Jeschke, A. Beri, M. Grüll Laparoscopic radioisotope-guided sentinel lymph node dissection in staging of prostate cancer Eur Urol 53 2008 126 132
139. A. Beri, G. Janetschek Technology insight: radioguided sentinel lymph node dissection in the staging of prostate cancer Nat Clin Pract Urol 3 2006 602 610
140. A. Hacker, S. Jeschke, K. Leeb Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: Comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection J Urol 176 2006 2014 2018 discussion 2018-2019
141. S. Corvin, D. Schilling, K. Eichhorn Laparoscopic sentinel lymph node dissection - A novel technique for the staging of prostate cancer Eur Urol 49 2006 280 285
142. S. Jeschke, T. Nambirajan, K. Leeb Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection J Urol 173 2005 1943 1946
143. U. Ganswindt, F. Paulsen, S. Corvin Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique Int J Radiat Oncol Biol Phys 67 2007 347 355
144. D.A. Silver, I. Pellicer, W.R. Fair Prostate-specific membrane antigen expression in normal and malignant human tissues Clin Cancer Res 3 1997 81 85
145. M.H. Pan, D.W. Gao, J. Feng Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy Mol Imaging Biol 11 2009 159 166
146. F. Dehdashti, J. Picus, J.M. Michalski Positron tomographic assessment of androgen receptors in prostatic carcinoma Eur J Nucl Med Mol Imaging 32 2005 344 350
147. G.S. Meirelles, H. Schöder, G.C. Ravizzini Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer Clin Cancer Res 16 2010 6093 6099
148. P. Sabbatini, S.M. Larson, A. Kremer Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer J Clin Oncol 17 1999 948 957
149. S. Hori, T. Jabbar, N. Kachroo Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer J Cancer Res Clin Oncol 137 2011 235 241
150. J. Rigaud, R. Tiguert, L. Le Normand Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy J Urol 168 2002 1423 1426
151. B. Wosnitzer, M. Ghesani Paradoxical response of prostate cancer skeletal metastases to androgen deprivation therapy Radiology Case Reports 5 2010 443
152. U. Ganswindt, D. Schilling, A.C. Müller Distribution of prostate sentinel nodes: A SPECT-derived anatomic atlas Int J Radiat Oncol Biol Phys 79 2011 1364 1372
153. L.S. Zuckier, M. Finkelstein, E.R. Kreutzer Technetium-99m antimony sulphide colloid lymphoscintigraphy of the prostate by direct transrectal injection Nucl Med Commun 11 1990 589 596
154. A. Mattei, F.G. Fuechsel, N. Bhatta Dhar The template of the primary lymphatic landing sites of the prostate should be revisited: Results of a multimodality mapping study Eur Urol 53 2008 118 125
155. U. Ganswindt, F. Paulsen, S. Corvin Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition BMC Cancer 5 2005 91
156. S. Minner, C. Wittmer, M. Graefen High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer Prostate 71 2011 281 288
157. S.F. Slovin Emerging role of immunotherapy in the management of prostate cancer Oncology (Williston Park) 21 2007 326 333 discussion 334,338,346-348
158. J.S. Ross, C.E. Sheehan, H.A. Fisher Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer Clin Cancer Res 9 2003 6357 6362
159. M.J. Burger, M.A. Tebay, P.A. Keith Expression analysis of delta-catenin and prostate-specific membrane antigen: Their potential as diagnostic markers for prostate cancer Int J Cancer 100 2002 228 237
160. N.H. Bander Technology insight: Monoclonal antibody imaging of prostate cancer Nat Clin Pract Urol 3 2006 216 225
161. D.B. Sodee, R.J. Ellis, M.A. Samuels Prostate cancer and prostate bed SPECT imaging with ProstaScint: Semiquantitative correlation with prostatic biopsy results Prostate 37 1998 140 148
162. N. Pandit-Taskar, J.A. O'Donoghue, M.J. Morris Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: Lesion detectability and dosimetric projections for 90Y radioimmunotherapy J Nucl Med 49 2008 1066 1074
163. N.H. Bander, E.J. Trabulsi, L. Kostakoglu Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen J Urol 170 2003 1717 1721
164. M.I. Milowsky, D.M. Nanus, L. Kostakoglu Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer J Clin Oncol 22 2004 2522 2531
165. M.J. Morris, C.R. Divgi, N. Pandit-Taskar Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer Clin Cancer Res 11 2005 7454 7461
166. A.K. Patri, A. Myc, J. Beals Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy Bioconjug Chem 15 2004 1174 1181
167. S. Vallabhajosula, S.J. Goldsmith, K.A. Hamacher Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: Radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen J Nucl Med 46 2005 850 858
168. N.H. Bander, M.I. Milowsky, D.M. Nanus Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer J Clin Oncol 23 2005 4591 4601
169. S. Vallabhajosula, S.J. Goldsmith, L. Kostakoglu Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: Effect of multiple treatments on myelotoxicity Clin Cancer Res 11 2005 7195s 7200s
170. S. Vallabhajosula, I. Kuji, K.A. Hamacher Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: Prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med 46 2005 634 641
171. J.P. Holland, V. Divilov, N.H. Bander 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo J Nucl Med 51 2010 1293 1300
172. S.M. Hillier, A.M. Kern, K.P. Maresca 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy J Nucl Med 52 2011 1087 1093
173. R.J. Ellis, D.B. Sodee, J.P. Spirnak Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy Int J Radiat Oncol Biol Phys 48 2000 683 687
174. R.J. Ellis, E.H. Zhou, P. Fu Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure J Urol 179 2008 1768 1773 discussion 1773-1774
175. Y. Seo, C.M. Aparici, M.R. Cooperberg In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT J Nucl Med 51 2010 31 36
176. R. Minamimoto, H. Uemura, F. Sano The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level Ann Nucl Med 25 2011 21 27
177. C. Hofer, C. Laubenbacher, T. Block Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy Eur Urol 36 1999 31 35
178. L.C. Costello, R.B. Franklin Citrate metabolism of normal and malignant prostate epithelial cells Urology 50 1997 3 12
179. D.E. Ponde, C.S. Dence, N. Oyama 18F-fluoroacetate: A potential acetate analog for prostate tumor imaging - In vivo evaluation of 18F-fluoroacetate versus 11C-acetate J Nucl Med 48 2007 420 428
180. A. Matthies, S. Ezziddin, E.M. Ulrich Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT Eur J Nucl Med Mol Imaging 31 2004 797
181. 18F-fluorocholine for prostate cancer imaging: A systematic review of the literature Prostate Cancer Prostatic Dis 15 2012 45 55
182. M. Beheshti, R. Vali, W. Langsteger [18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer Eur J Nucl Med Mol Imaging 34 2007 1316 1317 author reply 1318-1319
183. M. Cimitan, R. Bortolus, S. Morassut [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 2006 1387 1398
184. S.A. Kwee, H. Wei, I. Sesterhenn Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET J Nucl Med 47 2006 262 269
185. M. Heinisch, A. Dirisamer, W. Loidl Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: Meaningful at PSA < 5 ng/ml? Mol Imaging Biol 8 2006 43 48
186. D.T. Schmid, H. John, R. Zweifel Fluorocholine PET/CT in patients with prostate cancer: Initial experience Radiology 235 2005 623 628
187. S.A. Kwee, M.N. Coel, J. Lim Prostate cancer localization with 18fluorine fluorocholine positron emission tomography J Urol 173 2005 252 255
188. F. Wurschmidt, C. Petersen, A. Wahl [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes Radiat Oncol 6 2011 44
189. T. Steuber, T. Schlomm, H. Heinzer [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: Preliminary results from a prospective histology-based study Eur J Cancer 46 2010 449 455
190. G. Pascali, L. D'Antonio, P. Bovone Optimization of automated large-scale production of [(18)F]fluoroethylcholine for PET prostate cancer imaging Nucl Med Biol 36 2009 569 574
191. M. Zuhayra, A. Alfteimi, L. Papp Simplified fast and high yielding automated synthesis of [18F]fluoroethylcholine for prostate cancer imaging Bioorg Med Chem 16 2008 9121 9126
192. T. Hara, N. Kosaka, H. Kishi Development of (18)F-fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging J Nucl Med 43 2002 187 199
193. N. Oyama, H. Akino, Y. Suzuki FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation Nucl Med Commun 22 2001 963 969
194. G. Baronzio, A. Gramaglia, G. Fiorentini Review Current role and future perspectives of hyperthermia for prostate cancer treatment In Vivo 23 2009 143 146
195. M. Picchio, E. Giovannini, C. Crivellaro Clinical evidence on PET/CT for radiation therapy planning in prostate cancer Radiother Oncol 96 2010 347 350
196. A. Winter, J. Uphoff, R.P. Henke First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy Urol Int 84 2010 418 423
197. A. Winter, J. Uphoff, R.P. Henke Complete PSA remission without adjuvant therapy after secondary lymph node surgery in selected patients with biochemical relapse after radical prostatectomy and pelvic lymph node dissection Adv Urol 2012 2012 609612
198. E.Y. Yu, M. Muzi, J.A. Hackenbracht C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: Relative findings and response to therapy Clin Nucl Med 36 2011 192 198
199. J. Seppälä, M. Seppänen, E. Arponen Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer Radiother Oncol 93 2009 234 240
200. A.J. Breeuwsma, J. Pruim, M.M. Jongen In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer Eur J Nucl Med Mol Imaging 32 2005 668 673
201. M. Farsad, R. Schiavina, P. Castellucci Detection and localization of prostate cancer: Correlation of (11)C-choline PET/CT with histopathologic step-section analysis J Nucl Med 46 2005 1642 1649
202. B.J. Beattie, P.M. Smith-Jones, Y.S. Jhanwar Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET J Nucl Med 51 2010 183 192
203. A.B. Apolo, N. Pandit-Taskar, M.J. Morris Novel tracers and their development for the imaging of metastatic prostate cancer J Nucl Med 49 2008 2031 2041
204. J. He, Y. Wang, J. Feng Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment J Nucl Med 51 2010 427 432